Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
444 Unveiling immune-related adverse events (irAEs) and symptom burden in melanoma patients on adjuvant immune checkpoint inhibitors (ICIs)
Compose a Response to This Article
Other responses
No responses have been published for this article.
